Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 127 JPY -0.19%
Market Cap: 32.5B JPY
Have any thoughts about
Daito Pharmaceutical Co Ltd?
Write Note

Daito Pharmaceutical Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Daito Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Daito Pharmaceutical Co Ltd
TSE:4577
Cost of Revenue
-ÂĄ37.8B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
-4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cost of Revenue
-ÂĄ1.5T
CAGR 3-Years
-15%
CAGR 5-Years
-9%
CAGR 10-Years
-12%
Daiichi Sankyo Co Ltd
TSE:4568
Cost of Revenue
-ÂĄ420B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
-6%
Otsuka Holdings Co Ltd
TSE:4578
Cost of Revenue
-ÂĄ648.6B
CAGR 3-Years
-11%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cost of Revenue
-ÂĄ337.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-5%
Astellas Pharma Inc
TSE:4503
Cost of Revenue
-ÂĄ383.6B
CAGR 3-Years
-16%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
No Stocks Found

Daito Pharmaceutical Co Ltd
Glance View

Market Cap
32.5B JPY
Industry
Pharmaceuticals

Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Intrinsic Value
2 428.89 JPY
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Daito Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-37.8B JPY

Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Cost of Revenue amounts to -37.8B JPY.

What is Daito Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-4%

Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Daito Pharmaceutical Co Ltd have been -2% over the past three years , -2% over the past five years , and -4% over the past ten years .

Back to Top